Newsroom

Monarch Technologies receives CHF 40,000 from Venture Kick to accelerate validation toward clinical translation

16.06.2026

Monarch Technologies receives CHF 40,000 from Venture Kick to advance its adaptive drug delivery platform for locoregional cancer ... more

SonoStent receives CHF 40,000 from Venture Kick to advance non-invasive urinary stent technology

16.06.2026

SonoStent receives CHF 40,000 from Venture Kick to advance its ultrasound-activated technology for urinary stents and catheters. B ... more

Immitra Bio receives CHF 150,000 from Venture Kick to reimagine stem cell therapy for rare diseases

15.06.2026

The ETH spin-off Immitra Bio has received CHF 150,000 from Venture Kick to develop a new treatment approach for rare genetic disea ... more

more

Media contacts

For media enquiries, please email our communications team. If you have a general question about Venture Kick please visit our about us page.

Learn more about Venture Kick or download the latest annual report for detailed information.